US Physical Therapy Q2 revenue up 17.3%
Overview
US Physical Therapy Q2 revenue from physical therapy operations rises 17.3% driven by record patient visits
Adjusted EBITDA for Q2 beats analyst expectations, rising 21.4% to $26.9 mln
Company raises full-year 2025 earnings guidance, reflecting strong performance
Outlook
Company raises full-year 2025 Adjusted EBITDA guidance to $93.0 mln-$97.0 mln
Company expects continued growth in injury prevention services
Result Drivers
RECORD PATIENT VISITS - US Physical Therapy reports all-time high of 1,558,756 patient visits in Q2 2025, a 16.7% increase from Q2 2024
CLINIC EXPANSION - Co added six clinics and acquired equity interests in new practices, contributing to revenue growth
IIP GROWTH - Industrial injury prevention services revenue rose 22.6% to $29.1 mln, driven by organic growth and acquisitions, per CEO Chris Reading
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 EPS | $0.58 | ||
Q2 Net Income | $12.40 mln | ||
Q2 Adjusted EBITDA | Beat | $26.90 mln | $24.50 mln (7 Analysts) |
Q2 Dividend | $0.45 |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy"
Wall Street's median 12-month price target for US Physical Therapy Inc is $107.00, about 32.1% above its August 6 closing price of $72.69
The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 26 three months ago
Press Release:
